Form 4 for TYRA Tyra Biosciences, Inc.
Accepted 2026-09-17 19:26:30 ET · period of report 2026-09-15 · accession 0001193125-26-394734 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-17 19:26 | 2026-09-15 | TYRA | Rueb Yuliya | VP, Fin (PAO) | A - Grant | $9.13 | +2,925 | 11.3K | +35% | +$26.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | A | A | 2,925 | $9.13 | 11,258 | D | — | — | (F1) These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. (F2) Includes restricted stock units. (F3) The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4. |